How is the Lille score calculated on day 7 of prednisolone therapy for severe alcoholic hepatitis, and what cutoff determines whether to continue or stop steroids?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 28, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Lille Score: Calculation and Clinical Application in Severe Alcoholic Hepatitis

The Lille score must be calculated on day 7 of prednisolone therapy using a specific formula incorporating six variables, and steroids should be discontinued if the score is ≥0.56, as these null responders have only 53.3% 28-day survival compared to 91.1% in complete responders. 1, 2

Formula and Calculation

The Lille score is calculated using the following formula 2:

R = 3.19 – 0.101 × age (years) + 0.147 × albumin day 0 (g/L) + 0.0165 × (bilirubin day 0 – bilirubin day 7 in μmol/L) – 0.206 × renal insufficiency – 0.0065 × bilirubin day 0 (μmol/L) – 0.0096 × prothrombin time (seconds)

Then: Lille score = exp(–R) / [1 + exp(–R)] 2

Required Variables:

  • Age in years (coefficient: -0.101) 2
  • Albumin at day 0 in g/L (coefficient: +0.147) 2
  • Bilirubin at day 0 in μmol/L (coefficient: -0.0065) 2
  • Bilirubin at day 7 in μmol/L (used to calculate evolution: day 0 minus day 7, coefficient: +0.0165) 2
  • Prothrombin time in seconds (coefficient: -0.0096) 2
  • Renal insufficiency (coded as 0 if creatinine <1.3 mg/dL or 1 if ≥1.3 mg/dL, coefficient: -0.206) 2

Critical Cutoff Values and Response Categories

The score ranges from 0 to 1 and stratifies patients into three distinct prognostic groups 1, 2:

  • Complete responders: Lille score ≤0.16 → 91.1% 28-day survival 1, 2
  • Partial responders: Lille score 0.16-0.56 → 79.4% 28-day survival 1, 2
  • Null responders: Lille score ≥0.56 → 53.3% 28-day survival 1, 2

An older threshold of 0.45 has also been validated, showing 6-month survival of 85% for scores <0.45 versus only 25% for scores >0.45 1.

Clinical Decision Algorithm

For Lille Score ≥0.56 (Null Responders):

Stop prednisolone immediately. 1, 3 These patients have significantly worse outcomes with continued steroids, and infection occurs more frequently in non-responders. 1 Consider alternative rescue therapies such as liver transplantation, as survival may be significantly higher with transplantation than continuing medical treatment alone. 1

For Lille Score 0.45-0.56 (Borderline Zone):

The decision requires individualized assessment based on 3:

  • Presence of infection
  • Trajectory of clinical deterioration
  • Availability of liver transplantation

However, the guideline-recommended cutoff of ≥0.56 provides clearer decision-making, and most guidelines support stopping steroids at this threshold. 1

For Lille Score <0.45 (Responders):

Continue prednisolone 40 mg daily for an additional 21 days with or without tapering. 1 These patients demonstrate clear treatment benefit with 6-month survival of 85%. 1

Timing Considerations

Standard assessment is at day 7 of corticosteroid treatment. 1, 2, 3 However, emerging evidence suggests the Lille score can be calculated at day 4 with similar prognostic performance, potentially allowing earlier identification of non-responders and reducing complications from prolonged steroid exposure. 2, 4 One study showed 90.3% of patients were correctly identified as responders or non-responders by day 4 compared to day 7. 4

Integration with Other Prognostic Tools

Combining the Lille score with MELD provides optimal risk stratification. 2, 3 The MELD score is used for baseline severity assessment and longer-term prognostication, while the Lille score guides immediate treatment decisions at day 7. 3 The best model for predicting 28-day mortality combines MELD with Lille score (either day 4 or day 7), achieving accuracy of 0.90. 4

Common Pitfalls and Caveats

  • Do not use the Lille score at baseline – it requires day 7 bilirubin to assess treatment response. 2
  • Ensure units are correct: bilirubin must be in μmol/L (multiply mg/dL by 17.1 to convert), albumin in g/L, and prothrombin time in seconds. 2
  • The score has excellent sensitivity (95%) but poor specificity (19%) for predicting 30-day survival, meaning it is better at identifying responders than non-responders. 5
  • Baseline prothrombin time may predict steroid response – higher baseline PT is associated with non-response (OR = 2.954), potentially allowing earlier identification of futile therapy. 6

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Lille Score Calculation and Clinical Application

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Alcoholic Hepatitis Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Research

Prothrombin time predicts steroid response in severe alcohol-related hepatitis.

Liver international : official journal of the International Association for the Study of the Liver, 2024

Related Questions

What is the Lille score in patients with severe alcoholic hepatitis?
What is the formula to calculate the Lille score (Liver Disease severity score)?
What Lille score (Model for End-Stage Liver Disease score) indicates futility of corticosteroids (e.g. prednisone) and necessitates urgent liver transplantation?
What are the clinical presentations of alcoholic hepatitis?
How do I diagnose and manage alcoholic hepatitis in an adult heavy drinker presenting with recent jaundice, right‑upper‑quadrant pain, fever, nausea or weight loss, including laboratory criteria (AST 2–3 × ALT, bilirubin, INR, leukocytosis), imaging findings, exclusion of other causes, severity scoring (Maddrey's Discriminant Function, MELD), and treatment options (abstinence, nutritional support, corticosteroids, pentoxifylline, management of ascites, encephalopathy, infection, transplant referral, adjunctive therapies)?
What is the recommended therapy and dosing strategy for sacubitril‑valsartan in an adult with chronic congestive heart failure (EF ≤40%, NYHA II‑IV) and coexisting hypertension?
How should I monitor the progression of alcoholic cirrhosis?
How should I manage an adult with chronic kidney disease‑related anemia who is not responding to roxadustat?
Can romiplostim and ferric carboxymaltose be administered together?
How do mutations in the target gene or silencing machinery influence the efficacy and safety of gene‑silencing therapies (RNA interference, antisense oligonucleotides, CRISPR interference)?
Is a single 250 µg subcutaneous injection of romiplostim appropriate?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.